Rotablator: Landmark Clinical Trials

Rotablator (Rotational Atherectomy System) is a specialized tool used to “drill” through heavy calcium deposits within coronary arteries. While a standard angioplasty uses a balloon to stretch an artery, that often isn’t enough when the plaque is as hard as bone, that is heavily calcified. That’s where this system comes in. A brief review of three important clinical trials, including one comparing rotablator with other modalities like intravascular lithotripsy and excimer laser coronary angioplasty follows.

---

How It Works: The “Diamond Drill”

The device consists of a tiny, olive-shaped burr coated with diamond chips. It is threaded into the artery over a specialized guidewire (the RotaWire).

• High-Speed Rotation: The burr spins at incredibly high speeds—typically between 140,000 and 190,000 RPM.
• Differential Cutting: This is the “magic” of the Rotablator. It uses a principle called differential cutting, which means it grinds away hard, calcified (inelastic) material while the healthy, elastic arterial wall simply deflects out of the way.
• Micro-particulates: The calcium is pulverized into millions of tiny particles (smaller than red blood cells), which then pass harmlessly through the capillary bed and are filtered by the body.

When is it used?

It is primarily used for complex, heavily calcified lesions where:

1. A standard balloon cannot be fully expanded (undilatable lesions).
2. The blockage is too hard for a stent to be properly deployed or “apposed” against the vessel wall.

Key Equipment Components

Component	Function
Advancer	The handpiece used by the cardiologist to move the spinning burr forward and backward.
Console	Controls the RPMs and monitors the “drop” in speed during ablation.
Compressed Gas	Nitrogen or dry air is used to drive the turbine that spins the burr.
Rota-Flush	A cocktail of saline, heparin, and vasodilators (like nitroglycerin or verapamil) used to lubricate the burr and prevent vasospasm.

Risks and Considerations

While highly effective, rotablation carries specific risks compared to standard PCI:

• Slow Flow / No Reflow: If too many micro-particles are released too quickly, they can temporarily clog the distal capillaries.
• Vessel Perforation: A rare but serious risk if the burr exits the vessel lumen.
• Heat Generation: High-speed spinning generates heat, which is why “short runs” (15–20 seconds) and constant irrigation are vital.

---

PREPARE-CALC trial

This is perhaps the most significant modern trial for Rotablator. It compared upfront rotablation against “modified balloons” (cutting or scoring balloons), before biodegradable polymer sirolimus-eluting stent (SES) implantation. Five year outcome of PREPARE-CALC trial was published in 2024. Study had 200 patients with 1:1 randomization.

Rotablation was superior in achieving “strategy success” (successful stent delivery and expansion) compared to modified balloons, particularly for longer calcified lesions. Modified balloons may be better for shorter lesions. One limitation mentioned is that scoring (rather than cutting) balloons were used in most cases in the modified balloon group.

At 5 years, Rotablation showed a significant reduction in Target Lesion Revascularization (TLR) compared to modified balloons in patients with severely calcified coronary lesions.

ROTA-CUT randomised trial

ROTA-CUT randomised trial investigated whether combining rotablation with a cutting balloon (RA+CBA) is better than rotablation with a standard non-compliant balloon (RA+NCBA).

Minimum Stent Area (MSA) on intravascular ultrasound (IVUS) was similar between the two groups. The study had 60 patients with coronary artery disease who underwent PCI for moderately or severely calcified lesions with drug-eluting stent implantation. The procedure was safe with rare procedural complications and few clinical adverse events at 30 days.

ROLLER COASTR-EPIC22 Trial

ROLLER COASTR-EPIC22 Trial compared rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), and intravascular lithotripsy (IVL) for the treatment of patients with moderate to severe calcified coronary stenosis. The primary endpoint assessed was the percentage of stent expansion by optical coherence tomography (OCT). There were 57 patients in each arm of the study. Intravascular lithotripsy was noninferior to rotablation in terms of stent expansion. ECLA did not reach this noninferiority level compared to rotablation. Minimum stent area, procedural success rates and complications were similar between the three arms.